Although hypertrophic scarring affects ~91% of burn patients annually, there is no drug to prevent this common complication. Hypertrophic scars are a fibroproliferative disorder, caused by dysregulated wound healing. This can be characterised by persistent myofibroblast transformation and the excessive accumulation of extracellular matrix (ECM).
Our research has focussed on developing a high-throughput screening assay that utilises the myofibroblast phenotype, to identify novel drugs that could be repurposed as a therapeutic for the prevention of hypertrophic scarring.
Contact MTRC@aru.ac.uk for more information.